Ind. J. Pharm. Edu. Res., 2023; 57(2s):s189-s197.
https://www.ijper.org

Review Article

PLGA: A Wow Smart Biodegradable Polymer in Drug Delivery System

Sonali S Sonawane[1], Prashant L Pingale[1,*], Sunil V Amrutkar[2]

[1]Department of Pharmaceutics, GES's Sir Dr. M. S. Gosavi College of Pharmaceutical Education and Research, Nashik, Maharashtra, INDIA.
[2]Department of Pharmaceutical Chemistry, GES's Sir Dr. M. S. Gosavi College of Pharmaceutical Education and Research, Nashik, Maharashtra, INDIA.

ABSTRACT

Aim: This article describes how biodegradable polymers and their drug delivery mechanisms can be used to monitor and maintain local or targeted drug distribution. Polylactic-co-glycol acid has been one of the most appealing polymeric candidates for creating drug release and tissue engineering products over the last couple of decades. PLGA has a variety of purposes due to its biodegradability and biocompatibility. **Materials and Methods:** The enclosed medicine is delivered from PLGA microparticles via diffusion bulk erosion of the biopolymer, with the diffusion rate mainly observed by the drug distributing and partition coefficient. Microparticles with customization and time-controlled drug release can be fabricated. **Results:** Drugs as anticancer agents, anti-inflammatory non-steroidal, and nutraceutical were favorably close in microparticles made by different methods. Advances in nanobiotechnology have led to a wide range of new technologies which could be used to improve drug delivery rates. Manufacturing methods for PLGA Properties associated nanoparticles, as well as their promising pharmacological uses, also including drug carriers Polymers are involved in making safe and effective immunization, drug, and gene delivery mechanisms using well-described, repeatable fabrication procedures. It has a huge variety of erosion times, unsuitable physical properties, and most fundamentally, FDA approval polymer content. **Conclusion:** The FDA has approved PLGA for use in a variety of drug delivery systems. The appropriate release rates for pharmaceuticals can be accomplished by varying the lactic acid to glycolic acid ratio.

Keywords: PLGA, Biodegradable, Polymer, Drug delivery system, Biocompatible.

Correspondence:
Prashant L Pingale
Associate Professor, Department of Pharmaceutics, GES's Sir Dr. M. S. Gosavi College of Pharmaceutical Education and Research, Nashik-422005, Maharashtra, INDIA.
Email: prashantlpingale@gmail.com

Received: 23-12-2021;
Revised: 18-07-2022;
Accepted: 20-01-2023.

INTRODUCTION

Regulating the release of a drug, enhancing the solubility of drugs, loss drug degradation, lowering drug toxicity, and encouraging drug absorption regulation are all advantages of a drug delivery system based on polymer.[1] Some desirable characteristics of polymer for drug delivery systems should be.[2]

Natural or synthetic origin, lower toxicity, and biodegradable, Degradation *in vivo* at a predetermined rate, with degraded products easily excreted from the body. No poisonous endogenous impurities or residual chemicals, such as cross-linking agents, were used in their preparation.

Starch, chitosan, alginate, and collagen are examples of naturally derived polymers, while synthetic polymers include poly (alkyl cyanoacrylate), poly (anhydrides), and polyesters.[3] They include thermoplastic aliphatic polyesters including polylactic acid, polyglycolic acid, and particularly the copolymer PLGA, which have been used as biomaterials for biomedical applications based on toxicological and clinical evidence.[4] PLGA is a non-immunogenic, biodegradable, and non-toxic block polymer used in medical procedures and drug delivery systems. It has a controlled/sustained release pattern and a high bioavailability. "Along with its stimuli-responsive nature, PLGA is known as a smart polymer". A broad variety of drugs have benefited from nanotechnology to improve their pharmacokinetic profile and therapeutic effects. In the clinical trials, a large number of nanoparticle-based medical aid agents have participated in the last twenty years. In recent years, Polylactide (PLA) and its glycolide copolymers have gotten a lot of press as excipients for parenteral drug sustained release. PLGA is a category of FDA-approved biodegradable materials that have been extensively researched as medication, protein, and other small molecules DNA, RNA, and peptide delivery vehicles.[5]

PLGA Synthesis

A copolymer of poly(lactic-co-glycolic acid) is formed by irregular ring beginning polycondensation and ester bonding of

DOI: 10.5530/ijper.57.2s.23

monomer units, glycolic acid (y), and lactic acid cyclic(x) dimers and ester bonding (Figure 1).

Structure of PLGA[6]

D and L stereoisomers of lactic acid occur due to the asymmetrical ß-carbon, and the resulting polymer may be D, L, or racemic DL. The polymerization is completed as shown in Figure 2.[7]

Biodegradable

In vitro studies and clinical approach research on degradation, including preparation methods, small molecular mass compounds' design, scale, form, and morphology, as well as the polymer's internal properties (molecular weight, chemical structure, catalytic activity, crystalline nature, and thermal stability) and physicochemical properties. Less Molecular mass, water-soluble, and amorphous polymers, as well as copolymers with a stronger glycolide base, degrade quickly. Surface erosion of PLGA may occur in some circumstances, but bulk erosion is the most popular cause of degradation. This is accomplished by the system's continuous spontaneous depolymerization of ester bonds in the polymer backbone. For PLGA, there are three-phase biodegradation mechanism has been proposed. After irregular ester linkages, a significant reduction in the polymer's molecular weight is detected there was no noticeable weight loss just then, and no soluble monomeric products were made. This is followed by rapid impact strength and the formation of soluble monomer and polysaccharide compounds as well as a decrease in molecular weight. Ultimately, from the soluble oligomeric part, soluble monomer processes occur, leading to complete polymer degradation.[8]

Techniques used in PLGA preparation methods

PLGA can be conveniently manufactured in a variety of shapes and sizes. Injectable biodegradable and biocompatible PLGA particles such as microparticles and nanoparticles could be used for controlled-release dosage forms to avoid the cumbersome surgical insertion of bulky implants. The high drug content in PLGA-microspheres can be accomplished by modifying standard solvent removal processes, preparing multi-layered microparticles, and advancing new microparticles manufacturing techniques such as coaxial electrospray, hydrogel templates, microfluidics, and $scCO_2$.



Figure 1: Structure of PLGA.

The methods enlisted below

Emulsion solvent evaporation extraction methods.

Emulsification solvent diffusion method.

Supercritical fluid emulsion.

Coacervation.

Spray drying.

Hydrogel template method.

Microfluidic systems.

Membrane extrusion emulsification.

Particle replication in non-wetting templates technique.

Electrohydrodynamic atomization or electro-spraying.

Particles from gas saturated solutions method.

Researchers have produced several methods for producing polymeric nanoparticles. There are two key phases in most of these processes. Preparing an emulsification process is the first step. uninhibited prefabricated macromolecules or the precipitation of a polymer is second.[9,10]

Evaporation of the Emulsification Solvent

Evaporation of the emulsifying solvent is among the greater used procedures. The polymer and medicine are first to become a solution in a water-resistant liquid solvent, then emulsified in an aqueous phase with stabilizers, such as chloroform. Attachment sites to a greater shearing mechanism, such as an ultrasonic system, cause emulsification. Under reduced pressure the organic phase evaporates, leaving a fine watery diffusion of nanoparticles. Hydrophilic medicines are implicated using the double-emulsion approach, which involves mixing an aqueous drug solution with an organic polymer solution while vigorously swirling to generate a water-in-oil emulsion. The water-in-oil emulsion is mixed into a separate aqueous solution called a stabilizer to form the water-in-oil-in-water emulsion. The solvent is removed from the emulsion via evaporation.

Emulsification solvent diffusion

The solvent used to make the emulsion must be somewhat water-soluble. Under vigorous stirring, the polymeric solution is added to an aqueous mixture containing stability. After obtaining the oil-in-water emulsion, it is diluted with a considerable amount of pure water. As a result of this dilution, more organic solvent from the organic phase contained in the scattered droplets can permeate out of the droplets, resulting in polymer precipitation. The solvent must initially diffuse out into the outer aqueous dispersion media before vaporization can remove it from the system.



Figure 2: Poly(lactic-co-glycolic acid) (PLGA) hydrolysis.

Table 1: Factors affecting degradation and drug delivery system.

Factors	Effect
Effect of Composition	To evaluate the water insolubility and degradation process of a distribution matrix.
Effect of Crystallinity	Crystallinity, which has an indirect impact on the method of degradation.
Effect of molecular weight and size	Higher molecular weight polymer has been shown to degrade at a lesser rate. A polymer chain's diameter is related to its molecular mass.
Effect of Drug type	Based on the drug type, the working of drug-polymer membrane dissolution and drug desired release factors depend.
Effect of the Shape and Size matrix	The matrix degrades more quickly when the surface area ratio is higher.
Effect of pH	Alkaline and strongly acidic vehicles stimulate polymer decomposition.
Effect of Enzyme	Relatively because of findings that decomposition *in vivo* cannot be fully compared to *in vitro* evaluation, there are contradictory effects of enzymes on degradation processes such as hydrolytic and enzymatic cleavage.
Effect of Drug load	The levels of drug fill-up in the drug delivery form have an evidential impact on the proportion and period of drug release.

Emulsification reverse salting-out

A water-miscible solvent and a watery solution comprising the salting-out agent, such as magnesium chloride, and a colloidal stabilizer, such as polyvinyl pyrrolidone, are added to a water-miscible solvent like acetone under vigorous mechanical stirring. By increasing the diffusion of the water-miscible solvent into the aqueous phase, this oil-in-water emulsion stimulates the creation of nanoparticles when diluted with enough water. The dilution lowers the salt content in the continuous phase of the emulsion, forcing the polymer solvent to move out from the drop. The residual solvent and salting-out agent are removed using cross-filtering.

Nano-precipitation

It is commonly used to insert lipophilic medicines into carriers based on a polymer's surface deposition.

The polymer, solvent of polymer, and non-solvent are used to carry out nanoprecipitation. The solvent should be organic, water-mixable, and vaporization inhibit. Rapid solvent diffusion produces nanoparticles almost instantly. Under reduced pressure, the solvent is then extracted from the suspension.

Analysis techniques of PLGA

Following the physicochemical changes that occur during the disintegration of polymers into monomers and oligomers, as well as changes in polymer molecular weight over time, changes in various physical properties related to polymer size, crystallinity, and thermal characteristics, morphological changes over time, and changes in pH have been utilized to analyze the process of PLGA degradation.

- Analysis Techniques for Polymer Degradation:
- NMR (Nuclear Magnetic Resonance).
- HPLC (High-Performance Liquid Chromatography).
- DSC/TGA (Differential Scanning Calorimetry / Thermogravimetric Analysis).
- IR/FTIR (Infrared Spectroscopy / Fourier Transform Infrared Spectroscopy).
- SEM (Scanning Electron Microscope).
- Raman Spectroscopy.
- TOF-SIMS (Time of Flight -Secondary Ion Mass Spectrometry).

Factors affecting PLGA degradation

To improve the good features of PLGA, researchers must first study the elements that influence PLGA degradation and then build a drug delivery system that takes all of these aspects into account to make it more efficient and effective. One factor that

determines enclosed drug delivery from PLGA microspheres is the concentration of polymer in the organic solvent during preparation. The size of the drug delivery device, water exposure, and storage temperature and humidity all affect the physical properties of PLGA particles. These characteristics influence not only the biopolymer's ability to be formulated but also its breakdown amount is shown in Table 1. Table 1 indicates Factors affecting degradation and drug delivery system, it includes various factors viz. effects of composition, Crystallinity, pH, enzymes, drug load etc.

PLGA in controlled /sustained drug delivery system

For controlled drug release dosage, PLGA particles such as microspheres, microcapsules, nanocapsules, and nanospheres were used. PLGA can be conveniently manufactured in a variety of shapes and sizes. Among other properties, it has biocompatibility, drug stability, rational biodegradation catalysis, and thermal conductivity. PLGA nanoparticles encapsulating methotrexate-transferrin were developed to increase penetration across the cell membrane were formed in a recent. To allow drug conjugate permeability throughout the blood-brain barrier as an active site, folic acid was placed on the PLGA nanoparticles.[11] The tuberculosis-fighting thioridazine-encapsulated PLGA nanoparticles and tested alone in the zebrafish model and combination with rifampicin. In both zebrafish embryos and cells, thioridazine was highly toxic, but still, no damage was observed that after the compound was enclosed in PLGA Nanoparticles. A combination therapy improved the killing of *Mycobacterium tuberculosis* and *M. bovis* BCG in macrophages.[12] The Food and Drug Administration has approved PLGA, DSPE-PEG, and lecithin polymers for medical applications. To encompass poorly water-soluble drugs, The PLGA polymer allows a positively charged center to form. The personality of lecithin and DSPE-PEG agonists forms a lipid film with a PEG layer all over the PLGA nucleus.

Various nanoparticle-based drug release systems, particularly those that belong to biocomposite PLGA with different purposes, are being developed for use in cardiovascular diseases (CVDs). Regulated monitoring and drug delivery of atherosclerosis, cardiac infarction, stenting, coronary thrombosis, cerebrovascular accident, pulmonary blood clot, and other cardiovascular disorders have been the key focuses of cardiovascular research PLGA was established. Stress penetration to the interior of the clot has been shown to enhance thrombolysis. A single intravenous dose of PLGA nanoparticles was found to have a higher efficiency to the monocyte and coronary of the mouse heart. The processing of cytokines to a rat myocardial ischemic model using PLGA particles loaded with VEGF is shown to be instructional effective.[13] The Blood-Brain Barrier (BBB) prohibits drugs from travel the Central Nervous System (CNS), making them ineffective in neurodegenerative decades. PLGA is beneficial for this function. Loperamide-loaded PLGA nanocomposites were developed using a restricted process and illustrated that they can cross the BBB efficiently to use a monoclonal antibody for target area ligands opposite the transferrin receptor. PLGA nanomaterials were created for productive nicotine delivery to the brain to establish a neuroprotective effect toward Parkinsonism triggered by Reactive Oxygen Species. Curcumin is encapsulated in PLGA to increase its solubility and concentration in the CNS, resulting in a potent anti-inflammatory response. To build polymer composites with favorable characteristics, metal-based nanostructures (MNCs) have been integrated into PLGA. As MNCs are introduced into PLGA matrices, the physicochemical and biological properties of the materials are significantly altered, producing better properties than traditional composites. Electrical, electronic, antibacterial, and anticancer properties are only a few of the appealing features of MNS/PLGA composites. The formation of antimicrobial MNSs using nanoscience could be used to treat microbial infections.[14]

Figure 3, depicts use of PLGA as an excellent biodegradable polymer with properties like biodegradable, mechanical strength, easy modification, biocompatibility which apply to various drug delivery systems.

PLGA in parenteral drug delivery system

Effective manufacture and implementation, localized distribution Some of the advantages of these delivery systems feature site-specific activity, control drug action, improved patient comfort and support, and biological system reliability. Drug delivery, protein and genetic engineering, and the use of devices to treat diseases through the gastrointestinal, intravenous, respiratory, and transdermal routes all use biodegradable polymers. The polysaccharide was coated on PLGA nanoparticles to boost anticonvulsant potency via intranasal release because it can bind to cerebellar or mucosal membranes.

allowing nanoparticles to stay on the surface longer.[15] Dunn and colleagues pioneered *in situ* forming implants, which have gotten a lot of attention in recent years thanks to the use of PLGA as a carrier. Implants are made of PLGA that has been dissolved in a biocompatible solvent and carries drugs. Following injection via Subcutaneous or intramuscular and contact with soluble body fluids, the polymer solutions precipitate and form implants. Atrix Laboratories has several patents, and Merck and Alza are both



Figure 3: PLGA Salient Features and Applications.

working on related systems. Atrix has used this technique to grow two consumer products (Atridox® and Eligard) so far. Bodmeier created a new microparticle system that develops in real-time and received several patents for there is an internal step in these ISM-systems that includes drug-containing polymer structures as well as a transition zone that contains organic solvents with a surfactant, as well as an oil phase with a viscosity inducer and emulsifying agent. Lupron Depot, the parenteral prolonged formulation based on PLA polymers, was accepted in 1989 and became a commercial success. Copolymer PLGA were chosen as biocompatible suture polymers in the healthcare industry.[16] Biodegradable polymeric nanocarriers hold a lot of promise for improving the effectiveness regulated release of encapsulated drug, protein, peptide, Genetic material active moiety in drug delivery devices.

PLGA in ocular drug delivery system

Biopolymers are used in two kinds of controlled release systems. A drug center is lined by a rate-controlling degradable layer in one unit. In a different approach, the drug is delivered inside a degradable homogeneous polymer. A compound is suspended or dissolved in an organic volatile solvent using a polymer solution. The liquid product is evaporated to dryness after increasing emulsification in a continual aqueous phase using an emulsifying agent, yielding solid, drug-coated polymer particles. Retinoic acid, for example, is a hydrophobic substance that can be quickly inserted into the polymer matrix.[17] Hydrophilic medicines, on the other hand, are not desirable for the water vapor of formal oil in water solvents. Crystallinity components of the drug form microspheres and scatter into the outer aqueous solution during pharmaceutical development as a consequence, compound locking and the rupturing effect are minimal. To make Microparticle include hydrophilic agents like ganciclovir or doxorubicin hydrochloride, some changes are needed[18] conjunctival, at the scleral, in the visual axis, or the vitreous body, biodegradable polymeric devices may be inserted. Antimetabolite-containing polyanhydride implants have been extensively researched as subconjunctival implants to avoid thrombosis following glaucoma surgery. PLGA discs with 5-FU have been also issued for a related purpose.[19] This form of insert device developed 5-FU for four weeks in visible site and substantially improved the stability of purification venous sinus in rabbits as differentiate to control eyes. Apel scientists created PLGA discs containing cyclosporin that's for corneal transplantation surgery. The systems administered the drug at 3 mg/day for the first 15 days, 0.5 mg/day in around days 15 and 100, and then the last 6 mg/day after day 200 in an *in vitro* experiment. Systems carrying cyclosporin were tested in rabbits. A longer time for clinical outcome. The devices were well tolerated, according to histological examination. Sustained-release steroid systems in the anterior chamber have been studied to regulate postoperative inflammation following cataract surgery. Morita and his colleagues.[20] PLGA-polyvinyl pyrrolidone rods with fluorometholone were prepared. The amount of polyvinyl pyrrolidone present may be used to regulate the drug release. For one month, the system held a constant amount of fluorometholone in the aqueous content and was well received by rabbit paws. Surodexz®, a novel dexamethasone delivery device for the treatment of inflammation following eye surgery, completed human research.[21] Surodex is a PLGA rod that contains 60 g of dexamethasone and delivers it for 7–10 days. Surodex was found to be stable and successful in reducing postoperative contamination after uncomplicated cataract surgery in a multicenter, supervised, double-masked, parallel-group study. Over the last twenty years, biodegradable polymeric processes for ocular drug carriers have been extensively studied. New biodegradable polymers for ophthalmic use, along with polyanhydrides and poly orthoesters, are being developed to replace PLGA in most drug delivery applications. Polymeric drug release systems can increase drug bioavailability while lowering side effects. As a result, the polymer's bioactivity in the ocular is a key factor for therapeutic use.

PLGA in gene-drug delivery system

Successful gene therapy has been hampered by the inability to deliver nucleic acid to target cells safely and effectively. PLGA nanoparticles can be used to effectively spread drugs and genes. There are several obstacles to using PLGA as a gene carrier. Although PLGA nanoparticles can cover encoded DNA from *in vivo* erosion, DNA releasing is low, and the negative charge makes DNA integration and delivery difficult. Furthermore, during the preparation process, DNA may be exposed to high compressive stresses and organic solvents, resulting in its inactivation. PLGA Nanoparticles may also be modified with different agents to minimize cytotoxicity, improve delivery performance, and target particular tissues/cells. The numerous methods for preparing PLGA NPs as gene carriers, as well as new techniques for altering PLGA particles that have been used in recent gene therapy studies, are summarized in this study.[22]

PLGA in transdermal drug delivery system

Researchers used a different philosophy to transdermal drug delivery as microneedle materials that provide a link between the user of polyglycolic acid and its co-polymers (PLGA), which have a long history of biocompatibility as bioabsorbable sutures and are economically viable and developing immune. For the three-dimensional culture of skin fibroblastic cells, a thin biodegradable interlocking together as a mesh of synthetic PLGA and naturally derived cartilage was used. Collagen microparticles were placed in the spaces of a PLGA mesh to create the synthetic knit. The collagen microparticles that formed in the PLGA knit openings improved cell proliferation and diffusion, promoting the rapid formation of uniformly thickened dermal tissue. Skin tissue engineering may benefit from PLGA–collagen hybrid mesh.[23]

PLGA in bone tissue engineering

Other very usually utilized biodegradable polymeric materials for third-dimensional scaffolds in tissue application science are soluble polylactic acid and polyglycolic acid, along with poly(lactic-co-glycolide) copolymers.[24-25] PLGA is often made from a material, such as a bioglass, or altered to make it more biomimetic and capable of bone regeneration.[26] Scaffolds, fibers, hydrogels, and injectable microspheres are all examples of PLGA-based bone replacements. The focus will be on PLGA-based polymers that can be modified, as well as hydroxyapatite, an inorganic additive commonly used in bone regeneration for its not toxic, immunogenicity, and ionic conductivity, as well as its similarity to natural bone minerals and a wide variety of types.[27]

Applications in Bone Tissue Engineering

Porous PLGA-Hydroxyapatite Scaffolds

To make three-dimensional porous scaffolds in recent years, porogen percolating, gas up, phase splitting, and solid free form methods have all been used.[28-32] Many groups have adopted the porogen leaching method, which has the advantages of being simple to implement by changing the size and volume of porogen, it is possible to regulate pore size and porosity effectively. So many studies in the publication address the use of particulate leaching to prepare process theories including PLGA and bioceramic particles.[33] Using gas-forming and particulate leaching (GF/PL), Kim *et al* discovered a new technique for inventing a polymeric HA composite scaffold without the use of organic compounds.[34]

Fibrous Scaffolds

The enhanced material characteristics, bioactivity, and fiber formability of the scaffolds are thought to hold a lot of promise in terms of bone tissue regeneration. In the literature, various fiber-forming methods for fabricating micro and nanofibrous composite scaffolds have been propose.[35] Morgan used the wet-spinning method to create hollow fibers that were then combined with natural bone recovery and development using human bone marrow stromal cells.[36]

Hydrogels

Hydrogels are a different form of bioengineering scaffold. Hydrogels containing fibrin, hyaluronic acid, and Pluronic F127 results showed promise in the delivery of growth factors.[37] Hydrogels for bone regeneration have some drawbacks, such as poor structural rigidity, which limits their use as specific bone substitutes.[38]

Injectable Microspheres

Since they provide a more uniform mixture of active species in the polymer chain, amorphous PLGA copolymers are fitted for biosciences.[39] Kang *et al*. submerged mice for five days at 37°C in simulated body fluid.[40] PLGA microparticles with HA coatings, a predefined sequence with water/oil/water. After 6 weeks, bone formation was determined in the mice's subcutaneous dorsum after injections of apatite-coated PLGA microspheres containing osteoblasts. The apatite-coated PLGA microspheres group had significantly more bone regeneration than the plain PLGA microspheres group.[41]

PLGA in skin tissue engineering

In this analysis, the surface-modified multi-pore size PLGA scaffold was the most successful for cell culture. A two-step molding method was used to construct PLGA scaffolds to avoid the evolution of a polymer liner layer on the surface of the scaffolds. In the scaffold, there was no evidence of a skin layer. In PBS solution, different pore size specimens degraded more and faster than identical pore size organisms. Hydrophobic coating of the specimens layer improves the scaffold's cytocompatibility.[42]

PLGA in anticancer drug delivery system

Cancer is a major health issue that affects millions of people around the world.[43]

Cancer treatment entails a broad range of experimental endeavors aimed at determining the cause of cancer and developing specific approaches for avoidance, detection, therapy, and cure. To increase the deadly result during the tumor growth process while avoiding drug exposure to stable adjacent cells, anticancer drugs must be delivered at the site of action in a targeted and controlled manner. It's also essential to keep the drug diffusion rate constant in the tumor to optimize drug exposure to cell division, which leads to symptom improvement.[44] A current research topic is the advancement of novel anti-cancer drug production processes. Abraxane®, an Abraxis Oncology paclitaxel-based albumin formulation, Nanoxel®, a DaburPharma paclitaxel nano liposome, and Doxil®, an Ortho Biotech doxorubicin nano liposome, are all well-known commercial products.[45-50] Nanotechnology delivery systems have many benefits for the delivery of anticancer drugs, along with the freedom to transport into the smallest capillaries due to their lightweight and the ways to protect phagocyte removal, enabling them to remain in the bloodstream for longer periods.[51] PLGA nanoparticles often have broad active sites and molecular structure, allowing them to be conjugated to a variety of diagnostic agents, such as visual, radioisotopic, and magnetic. Nanoparticles, unlike other crystalline carriers in biological fluids, such as liposomes, are more opposite to enzymatic absorption.[52] Owing to its improved clinical level and poor water solubility and many other drugs that dissolve suitable for intravenous use, paclitaxel, a mitotic inhibitor, has seen little therapeutic use. As paclitaxel is incorporated into PLGA nanoparticles, it greatly increases anticancer efficacy as a balance to the Taxol, with the benefit even greater after longer incubation with cells. Findings from this study, the preparations that have been produced thus far

could be found effective methods for *in vivo* paclitaxel treatment.[53] Without the use of Tween®80, PLGA nanoparticles incorporate Docetaxel with the required size, and medicine fill-up properties for intravenous infusion can be produced. The cellular toxic impact of nanoparticles was stronger than even the free product. In contrast to a traditional Docetaxel formulation, docetaxel fill-up nanoparticles achieved good plasma concentration *in vivo* (Taxotere).[54] In photodynamic therapy, an agent sensitive to a substance or micro-organism is paired with a particular form of light to treat cancer. In the ovarian cancer cell model obtain from rats, this group utilized polymeric nanoparticles of PLGA as a drug transfer mechanism and correlated the nanoparticles' in-lab photoactivity to that free drug. The researchers discovered that hypericin-loaded nanoparticles had higher photosensitivity than the drug molecules and that enhancing the light level and treatment methods improved the action.

PLGA in mucus drug delivery system

Mucus clearance mechanisms and systemic absorption normally eliminate drugs delivered to mucous membranes effectively, preventing sustained drug presence locally. Drugs and genes embedded in polymeric particles can be delivered to mucosal tissues in a targeted and long-lasting manner.[55,56] Preventive mucus polymers help to assess for managed drug delivery at mucosal surfaces by trapping and rapidly removing dirt material from the eyes, digestive system, and women's reproductive tract. Some biodegradable polymer-based organic drug delivery systems, including non-ovulatory cervicovaginal mucilage, have been shown to get into extremely biocompatible human saliva. Biodegradable nanoparticles made of PLGA distributed at most 3,300-fold easy in CVM than liquid in concentrated human cervicovaginal mucus (CVM), which has a bulk viscosity around 1,800-fold higher than water at low shear.[57] Mucoadhesive nanoparticles may be used as a drug release strategy in oral therapy to improve therapeutic potential. The potential of developing HPMC and PLGA-based nanoparticles as a mucoadhesive time-release drug delivery system for sitagliptin using a nanospray drier was evaluated in an animal study in this research.[58]

CONCLUSION

Biodegradable polymers have demonstrated their ability to be used to produce new, advanced, and effective drug delivery systems. The FDA has approved PLGA for use in a variety of drug delivery systems. The appropriate release rates for pharmaceuticals entrapped in PLGA microparticles can be accomplished by varying the lactic acid to glycolic acid ratio and changing the physicochemical parameters. The safety, biodegradability, and biocompatibility of PLGA polymer are the primary factors that contribute to its widespread use and success. As a means of informing the development of the next targeted drug delivery, there is a considerable requirement for creativity in the design of time-saving approaches for managing the parameters that causing encapsulated drug and release characteristics.

CONFLICT OF INTEREST

The authors declare that there is no conflict of interest.

ABBREVIATIONS

BBB: Blood-brain barrier; **BCG:** Bacillus Calmette–Guérin; **CNS:** Central Nervous System; **CVDs:** Cardiovascular Diseases; **CVM:** Cervicovaginal Mucus; **DNA:** Deoxyribonucleic acid; **DSPE-PEG:** 1,2-Distearoyl-sn-glycero-3-phosphoethanolamine-Poly(ethylene glycol); **FDA:** Food and Drug Administration; **FU:** Fluorouracil; **HA:** Hydroxyapatite; **ISM:** *In situ* forming microparticle; **MNCs/MNS:** Metal-based nanostructures; **NPs:** Nanoparticles; **PLA:** Polylactic acid; **PLGA:** Polylactic-co-glycol acid; **RNA:** Ribonucleic acid; **$scCO_2$:** Supercritical carbon dioxide; **VEGF:** Vascular endothelial growth factor.

SUMMARY

Injectable biodegradable and biocompatible PLGA particles could be used for controlled-release dosage forms to avoid the cumbersome surgical insertion of bulky implants. The high drug content in PLGA-microspheres can be accomplished by modifying standard solvent removal processes and preparing multi-layered microparticles. PLGA can be conveniently manufactured in a variety of shapes and sizes. It has biocompatibility, drug stability, rational biodegradation catalysis, and thermal conductivity. Various nanoparticle-based drug release systems are being developed for use in cardiovascular diseases. The FDA has approved PLGA for use in a variety of drug delivery systems. The appropriate release rates for pharmaceuticals entrapped in PLGA microparticles can be accomplished. There is a considerable requirement for creativity in the design of time-saving approaches for managing the parameters that causing encapsulated drug and release characteristics. Biodegradable polymers and their drug delivery mechanisms can be used to monitor and maintain local or targeted drug distribution. PLGA has a variety of purposes due to its biodegradability and biocompatibility. Microparticles with customization and time-controlled drug release can be fabricated.

REFERENCES

1. Vilar G, Tulla-Puche J, Albericio F. Polymers and drug delivery systems. Curr Drug Deliv. 2012;9(4):367-94. doi: 10.2174/156720112801323053, PMID 22640038.
2. Gunatillake PA, Adhikari R. Biodegradable synthetic polymers for tissue engineering. Eur Cell Mater. 2003;5(1):1-16; discussion 16. doi: 10.22203/ecm.v005a01, PMID 14562275.
3. Coelho JF, Ferreira PC, Alves P, Cordeiro R, Fonseca AC, Góis JR, *et al*. Drug delivery systems: Advanced technologies potentially applicable in personalized treatments. EPMA J. 2010;1(1):164-209. doi: 10.1007/s13167-010-0001-x, PMID 23199049.
4. Lü JM, Wang X, Marin-Muller C, Wang H, Lin PH, Yao Q, *et al*. Current advances in research and clinical applications of PLGA-based nanotechnology. Expert Rev Mol Diagn. 2009;9(4):325-41. doi: 10.1586/erm.09.15, PMID 19435455.

5. Bouissou C, Rouse JJ, Price R, Van der Walle CF. The influence of surfactant on PLGA microsphere glass transition and water sorption: Remodeling the surface morphology to attenuate the burst release. Pharm Res. 2006;23(6):1295-305. doi: 10.1007/s11095-006-0180-2, PMID 16715359.
6. Makadia HK, Siegel SJ. Poly lactic-co-glycolic acid (PLGA) as biodegradable controlled drug delivery carrier. Polymers. 2011;3(3):1377-97. doi: 10.3390/polym3031377, PMID 22577513.
7. Singh G, Kaur T, Kaur R, Kaur A. Recent biomedical applications and patents on biodegradable polymer-PLGA. Int J Pharm Pharm Sci. 2014;1(2):30-42.
8. Jain RA. The manufacturing techniques of various drug loaded biodegradable poly(lactide-co-glycolide) (PLGA) devices. Biomaterials. 2000;21(23):2475-90. doi: 10.1016/s0142-9612(00)00115-0, PMID 11055295.
9. Verma A, Ratnawat S, Gupta AK, Jain S. PLGA: A polymer of choice as nanocarrier's to achieve effective delivery of medicinal substances. Int J Pharm Sci Res. 2012;3(12):5087.
10. Elmowafy EM, Tiboni M, Soliman ME. Biocompatibility, biodegradation and biomedical applications of poly (lactic acid)/poly (lactic-co-glycolic acid) micro and nanoparticles. J Pharm Investig. 2019;49(4):347-80. doi: 10.1007/s40005-019-00439-x.
11. Parmar A, Jain A, Uppal S, Mehta SK, Kaur K, Singh B, *et al*. Anti-proliferate and apoptosis triggering potential of methotrexate-transferrin conjugate encapsulated PLGA nanoparticles with enhanced cellular uptake by high-affinity folate receptors. Artif Cells Nanomed Biotechnol. 2018;46(sup2):704-19. doi: 10.1080/21691401.2018.1468768, PMID 29745729.
12. Vibe CB, Fenaroli F, Pires D, Wilson SR, Bogoeva V, Kalluru R, *et al*. Thioridazine in PLGA nanoparticles reduces toxicity and improves rifampicin therapy against mycobacterial infection in zebrafish. Nanotoxicology. 2016;10(6):680-8. doi: 10.3109/17435390.2015.1107146, PMID 26573343.
13. Mir M, Ahmed N, Rehman AU. Recent applications of PLGA based nanostructures in drug delivery. Colloids Surf B Biointerfaces. 2017;159:217-31. doi: 10.1016/j.colsurfb.2017.07.038, PMID 28797972.
14. Zare EN, Jamaledin R, Naserzadeh P, Afjeh-Dana E, Ashtari B, Hosseinzadeh M, *et al*. Metal-Based nanostructures/PLGA nanocomposites: Antimicrobial activity, cytotoxicity, and their biomedical applications. ACS Appl Mater Interfaces. 2020;12(3):3279-300. doi: 10.1021/acsami.9b19435, PMID 31873003.
15. Kaur S, Manhas P, Swami A, Bhandari R, Sharma KK, Jain R, *et al*. Bioengineered PLGA-chitosan nanoparticles for brain targeted intranasal delivery of antiepileptic TRH analogues. Chem Eng J. 2018;346:630-9. doi: 10.1016/j.cej.2018.03.176.
16. Patel CM, Patel MA, Patel NP, Prajapati PH, Patel CN. Poly lactic glycolic acid (PLGA) as biodegradable polymer. Res J Pharm Technol. 2010;3(2):353-60.
17. Giordano GG, Refojo MF, Arroyo MH. Sustained delivery of retinoic acid from microspheres of biodegradable polymer in PVR. Invest Ophthalmol Vis Sci. 1993;34(9):2743-51. PMID 8344796.
18. Wada R, Hyon SH, Ikada Y. Lactic acid oligomer microspheres containing hydrophilic drugs. J Pharm Sci. 1990;79(10):919-24. doi: 10.1002/jps.2600791016, PMID 2280363.
19. Trope GE, Cheng YL, Sheardown H, Liu GS, Menon IA, Heathcote JG, *et al*. Depot drug delivery system for 5-fluorouracil after filtration surgery in the rabbit. Can J Ophthalmol. 1994;29(6):263-7. PMID 7834564.
20. Morita Y, Saino H, Tojo K. Polymer blend implant for ocular delivery of fluorometholone. Biol Pharm Bull. 1998;21(1):72-5. doi: 10.1248/bpb.21.72, PMID 9477172.
21. Chang DF, Garcia IH, Hunkeler JD, Minas T. Phase II results of an intraocular steroid delivery system for cataract surgery. Ophthalmology. 1999;106(6):1172-7. doi: 10.1016/S0161-6420(99)90262-2, PMID 10366088.
22. Ramezani M, Ebrahimian M, Hashemi M. Current strategies in the modification of PLGA-based gene delivery system. Curr Med Chem. 2017;24(7):728-39. doi: 10.2174/0929867324666161205130416, PMID 27919215.
23. Chen G, Sato T, Ohgushi H, Ushida T, Tateishi T, Tanaka J. Culturing of skin fibroblasts in a thin PLGA–collagen hybrid mesh. Biomaterials. 2005;26(15):2559-66. doi: 10.1016/j.biomaterials.2004.07.034, PMID 15585258.
24. Ambrose CG, Clanton TO. Bioabsorbable implants: Review of clinical experience in orthopedic surgery. Ann Biomed Eng. 2004;32(1):171-77. doi: 10.1023/b:abme.0000007802.59936.fc, PMID 14964733.
25. Mano JF, Sousa RA, Boesel LF, Neves NM, Reis RL. Bioinert, biodegradable and injectable polymeric matrix composites for hard tissue replacement: State of the art and recent developments. Compos Sci Technol. 2004;64(6):789-817. doi: 10.1016/j.compscitech.2003.09.001.
26. Lin HR, Kuo CJ, Yang CY, Shaw SY, Wu YJ. Preparation of macroporous biodegradable PLGA scaffolds for cell attachment with the use of mixed salts as porogen additives. J Biomed Mater Res. 2002;63(3):271-9. doi: 10.1002/jbm.10183, PMID 12115758.
27. Pan Z, Ding J. Poly(lactide-co-glycolide) porous scaffolds for tissue engineering and regenerative medicine. Interface Focus. 2012;2(3):366-77. doi: 10.1098/rsfs.2011.0123, PMID 23741612.
28. Zhang L, Webster TJ. Nanotechnology and nanomaterials: Promises for improved tissue regeneration. Nano Today. 2009;4(1):66-80. doi: 10.1016/j.nantod.2008.10.014.
29. Mikos AG, Thorsen AJ, Czerwonka LA, Bao Y, Langer R, Winslow DN, *et al*. Preparation and characterization of poly (L-lactic acid) foams. Polymer. 1994;35(5):1068-77. doi: 10.1016/0032-3861(94)90953-9.
30. Harris LD, Kim BS, Mooney DJ. Open pore biodegradable matrices formed with gas foaming. J Biomed Mater Res. 1998;42(3):396-402. doi: 10.1002/(sici)1097-4636(19981205)42:3<396::aid-jbm7>3.0.co;2-e, PMID 9788501.
31. Zhang R, Ma PX. Poly(α-hydroxyl acids)/hydroxyapatite porous composites for bone-tissue engineering. I. Preparation and morphology. J Biomed Mater Res. 1999;44(4):446-55. doi: 10.1002/(sici)1097-4636(19990315)44:4<446::aid-jbm11>3.0.co;2-f, PMID 10397949.
32. Zein I, Hutmacher DW, Tan KC, Teoh SH. Fused deposition modeling of novel scaffold architectures for tissue engineering applications. Biomaterials. 2002;23(4):1169-85. doi: 10.1016/s0142-9612(01)00232-0, PMID 11791921.
33. Zhang P, Wu H, Wu H, Lù Z, Deng C, Hong Z, *et al*. Jing X. Biomacromolecules. 2011;12(7):2667-80. doi: 10.1021/bm2004725, PMID 21604718.
34. McMahon RE, Wang L, Skoracki R, Mathur AB. Development of nanomaterials for bone repair and regeneration. J Biomed Mater Res B Appl Biomater. 2013;101(2):387-97. doi: 10.1002/jbm.b.32823, PMID 23281143.
35. Kim SS, Sun Park M, Jeon O, Yong Choi C, Kim BS. Poly(lactide-co-glycolide)/hydroxyapatite composite scaffolds for bone tissue engineering. Biomaterials. 2006;27(8):1399-409. doi: 10.1016/j.biomaterials.2005.08.016, PMID 16169074.
36. Puppi D, Piras AM, Chiellini F, Chiellini E, Martins A, Leonor IB, *et al*. Optimized electro- and wet-spinning techniques for the production of polymeric fibrous scaffolds loaded with bisphosphonate and hydroxyapatite. J Tissue Eng Regen Med. 2011;5(4):253-63. doi: 10.1002/term.310, PMID 20661867.
37. Morgan SM, Tilley S, Perera S, Ellis MJ, Kanczler J, Chaudhuri JB, *et al*. Expansion of human bone marrow stromal cells on poly-(dl-lactide-co-glycolide)(PDLLGA) hollow fibres designed for use in skeletal tissue engineering. Biomaterials. 2007;28(35):5332-43. doi: 10.1016/j.biomaterials.2007.08.029, PMID 17822756.
38. Bergman K, Engstrand T, Hilborn J, Ossipov D, Piskounova S, Bowden T. Injectable cell-free template for bone-tissue formation. J Biomed Mater Res A. 2009;91(4):1111-8. doi: 10.1002/jbm.a.32289, PMID 19107794.
39. Eyrich D, Brandl F, Appel B, Wiese H, Maier G, Wenzel M, *et al*. Long-term stable fibrin gels for cartilage engineering. Biomaterials. 2007;28(1):55-65. doi: 10.1016/j.biomaterials.2006.08.027, PMID 16962167.
40. Kang SW, Yang HS, Seo SW, Han DK, Kim BS. Apatite-coated poly (lactic-co-glycolic acid) microspheres as an injectable scaffold for bone tissue engineering. J Biomed Mater Res A. 2008;85(3):747-56. doi: 10.1002/jbm.a.31572, PMID 17896763.
41. Habraken WJ, Wolke JG, Mikos AG, Jansen JA. Injectable PLGA microsphere/calcium phosphate cements: Physical properties and degradation characteristics. J Biomater Sci Polym Ed. 2006;17(9):1057-74. doi: 10.1163/156856206778366004, PMID 17094642.
42. Lee JJ, Lee SG, Park JC, Yang YI, Kim JK. Investigation on biodegradable PLGA scaffold with various pore size structure for skin tissue engineering. Curr Appl Phys. 2007;7:e37-40. doi: 10.1016/j.cap.2006.11.011.
43. Utreja P, Jain S, Tiwary AK. Novel drug delivery systems for sustained and targeted delivery of anti- cancer drugs: Current status and future prospects. Curr Drug Deliv. 2010;7(2):152-61. doi: 10.2174/156720110791011783, PMID 20158482.
44. Shenoy D, Little S, Langer R, Amiji M. Poly(ethylene oxide)-modified poly(beta-amino ester) nanoparticles as a pH-sensitive system for tumor-targeted delivery of hydrophobic drugs. 1. *In vitro* evaluations. Mol Pharm. 2005;2(5):357-66. doi: 10.1021/mp0500420, PMID 16196488.
45. Miele E, Spinelli GP, Miele E, Tomao F, Tomao S. Albumin-bound formulation of paclitaxel (Abraxane ABI-007) in the treatment of breast cancer. Int J Nanomedicine. 2009;4:99-105. doi: 10.2147/ijn.s3061, PMID 19516888.
46. Gradishar WJ. Albumin-bound paclitaxel: A next-generation taxane. Expert Opin Pharmacother. 2006;7(8):1041-53. doi: 10.1517/14656566.7.8.1041, PMID 16722814.
47. Green MR, Manikhas GM, Orlov S, Afanasyev B, Makhson AM, Bhar P, *et al*. Abraxane, a novel cremophor-free, albumin-bound particle form of paclitaxel for the treatment of advanced non-small-cell lung cancer. Ann Oncol. 2006;17(8):1263-8. doi: 10.1093/annonc/mdl104, PMID 16740598.
48. Soundararajan A, Bao A, Phillips WT, Perez III R, Goins BA. 186Re-liposomal doxorubicin (doxil): *in vitro* stability, pharmacokinetics, imaging and biodistribution in a head and neck squamous cell carcinoma xenograft model. Nucl Med Biol. 2009;36(5):515-24. doi: 10.1016/j.nucmedbio.2009.02.004, PMID 19520292.
49. Safra T, Muggia F, Jeffers S, Tsao-Wei DD, Groshen S, Lyass O, *et al*. Pegylated liposomal doxorubicin (doxil): Reduced clinical cardiotoxicity in patients reaching or exceeding cumulative doses of 500 mg/m2. Ann Oncol. 2000;11(8):1029-33. doi: 10.1023/a:1008365716693, PMID 11038041.
50. Lyass O, Uziely B, Ben-Yosef R, Tzemach D, Heshing NI, Lotem M, *et al*. Correlation of toxicity with pharmacokinetics of pegylated liposomal doxorubicin (Doxil) in metastatic breast carcinoma. Cancer: Interdisciplinary. Int J Am Cancer Soc. 2000;89(5):1037-47.
51. Jung T, Kamm W, Breitenbach A, Kaiserling E, Xiao JX, Kissel T. Biodegradable nanoparticles for oral delivery of peptides: Is there a role for polymers to affect mucosal uptake? Eur J Pharm Biopharm. 2000;50(1):147-60. doi: 10.1016/s0939-6411(00)00084-9, PMID 10840198.
52. Liu X, Novosad V, Rozhkova EA, Chen H, Yefremenko V, Pearson J, *et al*. Surface functionalized biocompatible magnetic nanospheres for cancer hyperthermia. IEEE Trans Magn. 2007;43(6):2462-4. doi: 10.1109/TMAG.2007.894004.

53. Fonseca C, Simões S, Gaspar R. Paclitaxel-loaded PLGA nanoparticles: Preparation, physicochemical characterization and *in vitro* anti-tumoral activity. J Control Release. 2002;83(2):273-86. doi: 10.1016/s0168-3659(02)00212-2, PMID 12363453.
54. Esmaeili F, Dinarvand R, Ghahremani MH, Ostad SN, Esmaily H, Atyabi F. Cellular cytotoxicity and *in-vivo* biodistribution of docetaxel poly (lactide-co-glycolide) nanoparticles. Anti-cancer Drugs. 2010;21(1):43-52. doi: 10.1097/CAD.0b013e328331f934, PMID 19809300.
55. Dawson M, Wirtz D, Hanes J. Enhanced viscoelasticity of human cystic fibrotic sputum correlates with increasing microheterogeneity in particle transport. J Biol Chem. 2003;278(50):50393-401. doi: 10.1074/jbc.M309026200, PMID 13679362.
56. Lai SK, Wang YY, Hanes J. Mucus-penetrating nanoparticles for drug and gene delivery to mucosal tissues. Adv Drug Deliv Rev. 2009;61(2):158-71. doi: 10.1016/j.addr.2008.11.002, PMID 19133304.
57. Tang BC, Dawson M, Lai SK, Wang YY, Suk JS, Yang M, *et al*. Biodegradable polymer nanoparticles that rapidly penetrate the human mucus barrier. Proc Natl Acad Sci U S A. 2009;106(46):19268-73. doi: 10.1073/pnas.0905998106, PMID 19901335.
58. Nair AB, Sreeharsha N, Al-Dhubiab BE, Hiremath JG, Shinu P, Attimarad M, *et al*. HPMC- and PLGA-based nanoparticles for the mucoadhesive delivery of sitagliptin: Optimization and *in vivo* evaluation in rats. Materials (Basel). 2019;12(24):4239. doi: 10.3390/ma12244239, PMID 31861192.

Cite this article: Sonawane SS, Pingale PL, Amrutkar SV. PLGA: A Wow Smart Biodegradable Polymer in Drug Delivery System. Indian J of Pharmaceutical Education and Research. 2023;57(2s):s189-s197.